For the year ending 2025-12-31, CRVO had -$764,027 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,966,367 |
| Accretion of discount on marketable securities, net | 854,077 |
| Stock-based compensation expense | 1,448,634 |
| Prepaid expenses and other current assets | -638,355 |
| Deferred offering costs | 310,581 |
| Accounts payable | -67,322 |
| Accrued expenses and other liabilities | 834,157 |
| Grant receivable | -1,827,238 |
| Net cash used in operating activities | -23,449,963 |
| Purchase of marketable securities | 25,402,751 |
| Maturities of marketable securities | 43,500,000 |
| Net cash provided by (used in) investing activities | 18,097,249 |
| Proceeds from sale of common stock, prefunded warrants and common stock warrants | 0 |
| Sale of common stock under at-the-market sales agreement, net of issuance costs | 4,588,687 |
| Net cash provided by financing activities | 4,588,687 |
| Net (decrease) increase in cash and cash equivalents | -764,027 |
| Cash and cash equivalents at beginning of the year | 8,999,496 |
| Cash and cash equivalents at end of the year | 8,235,469 |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)